Disease · MONDO_0018305

chronic granulomatous disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic granulomatous disease. Diseases, record MONDO_0018305. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018305

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic granulomatous disease; Open Targets
Open Targets ID: MONDO_0018305; Open Targets
Other names: Bridges-Good syndrome, CGD, CGD - Chronic granulomatous disease, Chronic Granulomatous Diseases, Chronic granulomatous disease (disorder), Congenital dysphagocytosis, Congenital dysphagocytosis (disorder), Disease, Chronic Granulomatous, Diseases, Chronic Granulomatous, GRANULOMATOUS DIS CHRONIC, Granulomatous Disease, Chronic, Granulomatous Diseases, Chronic, Quie syndrome, chronic granulomatous disorder, chronic septic granulomatosis; Open Targets
Disease Ontology: DOID:3265; Disease Ontology
MeSH: D006105; MeSH
NCI Thesaurus: C26788; NCI Thesaurus
Orphanet: ORPHA:379; Orphanet
Highest stage of its drugs: Approval, for 1 of its 26 drugs, from DailyMed and TTD; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INTERFERON GAMMA-1B	CHEMBL1201564	Protein	Approval	DailyMed and TTD	6	3	3	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
PEGFILGRASTIM	CHEMBL1201568	Protein	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Phase 2	ClinicalTrials.gov	11	11	11	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets23

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	4	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
CD2	T-cell surface antigen CD2	1	T-cell surface antigen CD2 inhibitor	Unknown	https://conductscience.org/library/genes/914	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 3	https://conductscience.org/library/genes/1043	Drugs and targets
CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1438	Drugs and targets
CSF2RB	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1439	Drugs and targets
CXCR4	C-X-C chemokine receptor type 4	1	C-X-C chemokine receptor type 4 partial agonist	Phase 2	https://conductscience.org/library/genes/7852	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1/2	https://conductscience.org/library/genes/2280	Drugs and targets
IFNG	Interferon gamma	1	Interferon gamma inhibitor	Phase 1/2	https://conductscience.org/library/genes/3458	Drugs and targets
IFNGR1	Interferon gamma receptor	1	Interferon gamma receptor agonist	Approval	https://conductscience.org/library/genes/3459	Drugs and targets
IFNGR2	Interferon gamma receptor	1	Interferon gamma receptor agonist	Approval	https://conductscience.org/library/genes/3460	Drugs and targets

1 to 10 of 23

See all 23 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00426517	Donor Stem Cell Transplantation for Congenital Immunodeficiencies	Early phase 1	48	2021-05-11	Inherited Immune Deficiencies	ALEMTUZUMAB, BUSULFAN, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01998633	Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)	Phase 2	47	2018-06-01	Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX	ALEMTUZUMAB, FLUDARABINE, MELPHALAN	Its record names the disease	ClinicalTrials.gov
NCT02512679	Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells	Phase 2	20	2016-06-17	Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Transplantation, Genetic Diseases, Thalassemia, Pediatrics, Diamond-Blackfan Anemia, Combined Immune Deficiency, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Lymphoproliferative Disease, Metabolic Diseases	ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00578643	Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease	Phase 2	15	2018-11-09	Chronic Granulomatous Disease	ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT02282904	Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide	Phase 1/2	7	2020-05-01	Chronic Granulomatous Disease	BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINE, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01319851	Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	Not applicable	3	2015-03-09	Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia	ALEFACEPT	Its record names the disease	ClinicalTrials.gov
NCT01147042	Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease	Phase 4	2	2017-09-20	IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease	INTERFERON GAMMA-1B	Its record names the disease	ClinicalTrials.gov
NCT00023192	Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care	Phase 3	60		Chronic Granulomatous Disease	ALEMTUZUMAB, CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT03984890	Vitamin D3 For CGD Patients With BCGosis/Itis	Phase 2/3	50		Vitamin D3, Chronic-granulomatous Disease, BCG	CHOLECALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT05463133	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists	Phase 1/2	50		Chronic Granulomatous Disease	ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, SIROLIMUS, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25459642	RESULT	1	PubMed
40920799	DERIVED	1	PubMed
39413163	DERIVED	1	PubMed
37042921	DERIVED	1	PubMed
35113934	DERIVED	1	PubMed
31745699	DERIVED	1	PubMed
31599480	DERIVED	1	PubMed
26095669	DERIVED	1	PubMed
19965657	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018305

GET https://conductscience.org/api/diseases/v1/MONDO_0018305/drugs?page=2

API reference For AI assistants